SUPNSUPERNUS PHARMACEUTICALS, INC.vs its industry peers
A metric-by-metric comparison of SUPERNUS PHARMACEUTICALS, INC. against Pharmaceutical Preparations — valuation, growth, profitability, quality and total return, with each figure's rank within the peer group. Every value is Go-computed from SEC filings and delayed prices; ranks are sorted positions within the group only — descriptive, not advice.
| 기업 | Market cap | P/E (TTM) | P/B | P/S | Revenue growth (YoY) | Earnings growth (YoY) | EBIT margin | ROE | ROIC | Piotroski F | 1y total return | Dividend yield |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SUPN본 종목 | $1.7B#9 | — | 1.6x#3 | 2.4x#1 | 8.6%#11 | -152.2%#13 | -8.7%#5 | -3.6%#6 | -4.8%#5 | — | -46.5%#12 | — |
| XERS | $1.9B#2 | — | — | 6.5x#4 | 43.7%#8 | 101.0%#3 | 8.5%#3 | — | 20.6%#1 | — | 5.6%#5 | — |
| ZBIO | $1.9B#3 | — | 7.6x#9 | 188.2x#10 | 100.0%#5 | -140.6%#12 | -3830.6%#12 | -152.9%#13 | -296.6%#8 | — | -7.6%#7 | — |
| AGIO | $1.9B#4 | — | 1.8x#4 | 34.7x#9 | 48.0%#6 | -161.3%#14 | -873.9%#10 | -40.3%#9 | — | — | -21.7%#9 | — |
| PGEN | $1.9B#5 | — | 42.5x#13 | 191.3x#11 | 146.7%#3 | -98.6%#11 | -1141.1%#11 | -575.1%#14 | -91.2%#7 | — | 24.5%#3 | — |
| GENB | $1.8B#7 | — | 3.9x#6 | — | — | — | — | 0.0%#3 | — | — | — | — |
| SLS | $1.8B#8 | — | 12.9x#11 | — | -100.0%#13 | 13.0%#6 | — | -19.5%#8 | — | — | 390.0%#1 | — |
| STOK | $1.8B#6 | — | 5.1x#7 | 9.7x#5 | 404.5%#2 | 92.3%#4 | -11.2%#6 | -2.0%#5 | — | — | 5.0%#6 | — |
| NUVB | $1.7B#10 | — | 6.6x#8 | 26.5x#7 | 699.0%#1 | 64.0%#5 | -338.7%#8 | -80.6%#11 | -87.4%#6 | — | -7.8%#8 | — |
| RARE | $1.7B#11 | — | — | 2.5x#2 | 20.2%#9 | -1.1%#7 | -79.5%#7 | — | — | — | -49.7%#13 | — |
| TRAX | $1.9B#1 | — | 12.8x#10 | — | — | -1.5%#8 | — | -110.0%#12 | — | — | — | — |
| KLRA | $1.6B#12 | — | 1.5x#2 | — | — | — | — | 0.0%#3 | — | — | — | — |
| ANIP | — | 15.6x#2 | — | — | 43.8%#7 | 510.5%#2 | 12.6%#2 | 13.1%#2 | 16.9%#2 | — | -23.7%#10 | — |
| INVA | $1.5B#13 | 4.9x#1 | 1.2x#1 | 3.7x#3 | 14.7%#10 | 1059.2%#1 | 39.8%#1 | 22.0%#1 | 14.7%#3 | 5#1 | 16.2%#4 | — |
| OCUL | $1.5B#14 | — | 2.9x#5 | 29.1x#8 | -18.5%#12 | -37.4%#10 | -519.8%#9 | -51.1%#10 | — | — | -39.6%#11 | — |
| ETON | $1.5B#15 | — | 31.4x#12 | 18.3x#6 | 104.9%#4 | -20.4%#9 | -1.1%#4 | -9.9%#7 | -1.8%#4 | 4#2 | 185.2%#2 | — |
Peer set: US filers sharing this company's SEC industry classification (SIC 2834). SIC is coarse — conglomerates and multi-segment companies map imperfectly. Values from SEC filings + delayed prices; ranks are within-group positions only. Market cap, P/E, P/B, P/S, 1y total return and dividend yield are computed from each member's latest snapshot price when the table is built (see as-of; snapshot prices can lag) — not live. Table built 2026-11-04.
Source: SEC XBRL filings + delayed prices · ranks are within-group positions · For reference only · Not investment advice